BeiGene Reports First Quarter 2018 Financial Results
read more...
May 04, 2018
BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference
read more...
May 01, 2018
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.
read more...
Apr 16, 2018
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
read more...
Apr 16, 2018
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
read more...
Apr 10, 2018
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
read more...
Apr 03, 2018
BeiGene Appoints J. Samuel Su to its Board of Directors
read more...
Mar 05, 2018
BeiGene to Present at Upcoming Investor Conferences
read more...
Feb 28, 2018
BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results
read more...
Feb 27, 2018
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
read more...
Feb 09, 2018
BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium
read more...
Feb 07, 2018
BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
read more...
Feb 05, 2018
BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China
read more...
Feb 05, 2018
BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium
read more...
Jan 31, 2018
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
read more...
Jan 22, 2018
BeiGene Announces Closing of $800 Million Public Offering
read more...
Jan 17, 2018
BeiGene Announces Pricing of $750 Million Public Offering
read more...
Jan 16, 2018
BeiGene Announces Proposed Public Offering
read more...
Jan 09, 2018
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
read more...
Jan 08, 2018
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region
read more...
